Plaque Psoriasis
Clinical guidelines for managing chronic autoimmune plaque lesions, identifying flare triggers, and utilizing targeted biologics.
🧠 Standard of Care & Symptoms
Plaque Psoriasis (Psoriasis Vulgaris) is a chronic autoimmune condition characterized by a rapid buildup of skin cells, leading to thick, red, scaly patches called plaques.
- Presentation: Raised, inflamed red patches covered with silvery-white scales (micaceous scale), most commonly on elbows, knees, scalp, and lower back. Plaques are often intensely itchy, painful, and prone to cracking or bleeding.
- Systemic Impact: Up to 30% of patients with plaque psoriasis develop psoriatic arthritis (PsA), a painful inflammatory joint disease requiring early systemic intervention.
- Triggers: Skin injuries (scratches, sunburns, or tattoos - known as the Koebner phenomenon), stress, smoking, alcohol, cold dry weather, and infections (especially streptococcal pharyngitis).
💊 Topical & Systemic Therapies
Psoriasis management ranges from localized topical treatments to broad systemic immunomodulators depending on severity.
Topical Regimens
- Corticosteroids: High-potency topical steroids (Clobetasol Propionate) are first-line for acute flares, but require rotational scheduling to avoid skin thinning (atrophy) or systemic absorption.
- Vitamin D Analogues: Calcipotriene or Calcitriol ointments normalize skin cell production rates and are often combined with corticosteroids for superior synergy.
- Topical Retinoids & Coal Tar: Tazarotene gels and coal tar preparations reduce inflammation and speed up descaling of stubborn plaques.
Systemic Non-Biologics
- Methotrexate: An oral folate antagonist that suppresses cell replication rates and is highly effective in managing concurrent joint pain.
- Apremilast (Otezla): An oral phosphodiesterase 4 (PDE4) inhibitor that regulates cellular inflammatory pathways.
🔬 Targeted Biologic Infusions
For moderate-to-severe plaque psoriasis, targeted biologics provide dramatic clearance, often achieving 90% to 100% skin clearance (PASI 90/100).
- IL-23 Inhibitors (Risankizumab / Skyrizi, Guselkumab / Tremfya): Target the p19 subunit of interleukin-23 to halt the inflammatory cell pathway with highly durable clearance and convenient quarterly dosing.
- IL-17 Inhibitors (Secukinumab / Cosentyx, Ixekizumab / Taltz): Block interleukin-17A directly, resolving plaques rapidly, particularly in difficult areas like nails, scalp, and palms/soles.
- TNF-Alpha Inhibitors (Adalimumab / Humira, Etanercept / Enbrel): Block tumor necrosis factor alpha, helping control both skin plaques and joint inflammation.
📊 Disease Severity & Classification
Dermatologists classify plaque psoriasis severity based on the body surface area (BSA) affected and the Psoriasis Area and Severity Index (PASI) score:
- Mild Psoriasis (BSA < 3% or PASI < 5): Affects isolated areas of the body. Typically manageable with localized topical ointments alone.
- Moderate Psoriasis (BSA 3% - 10% or PASI 5 - 10): Affects larger surface areas, making daily tasks or self-care difficult. Candidates for phototherapy or systemic treatments.
- Severe Psoriasis (BSA > 10% or PASI > 10): Extensive plaque involvement, often covering large portions of the trunk, limbs, and scalp. Requires advanced systemic non-biologic or targeted biologic therapy.
🔬 Active Clinical Trials
Clinical trials are currently investigating oral TYK2 inhibitors, next-generation bispecific cytokine blockers, and non-steroidal topical formulations.
Evaluating a novel oral TYK2 inhibitor against apremilast in patients with moderate-to-severe plaque psoriasis.
Key Inclusion: Diagnosis of plaque psoriasis for ≥ 6 months, PASI ≥ 12, and BSA ≥ 10% at baseline.Evaluating the long-term safety and clearance duration of an investigational dual-action bispecific antibody.
Key Inclusion: Moderate-to-severe plaque psoriasis candidate for systemic therapy; no prior exposure to IL-23 p19 subunit inhibitors.Testing a novel local cutaneous cytokine inhibitor ointment designed to avoid skin thinning side effects.
Key Inclusion: Mild-to-moderate plaque psoriasis with BSA 2% to 8% (excluding scalp/nails).🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with Plaque Psoriasis, follow these active steps to manage symptoms and reduce flares:
- Do Not Scratch or Pick Scales: Picking scales off can trigger the Koebner phenomenon, causing new plaques to erupt on the damaged skin site.
- Moisturize Daily: Use thick, fragrance-free creams or ointments (like ceramides or petroleum jelly) immediately after bathing to lock in moisture and soften scales.
- Avoid Known Flare Triggers: Manage stress, limit alcohol consumption, quit smoking, and protect your skin from scrapes, cuts, and severe sunburns.
- Schedule a Joint Screen: Discuss any morning stiffness or joint pain with your dermatologist to screen for early psoriatic arthritis.
❓ Patient FAQ
Q: Is plaque psoriasis contagious?
A: No. Psoriasis is an autoimmune condition caused by genetics and immune system overactivity. It cannot be caught or transmitted from person to person.
Q: Can diet help clear my psoriasis?
A: While diet alone cannot cure psoriasis, anti-inflammatory diets (rich in omega-3 fatty acids, olive oil, and leafy greens) and weight loss can help reduce systemic inflammation and improve treatment response.